The Collagen Market Is Booming. The Testing Hasn't Kept Up.

The collagen supplement market crossed $9.3 billion globally in 2023. Analysts at Grand View Research project it reaches $16.7 billion by 2030 — a compound annual growth rate of roughly 8.6%. Walk through any health food store or scroll any supplement retailer’s website and you’ll see it: marine collagen peptides, bovine collagen powder, “Type I & III” capsules, beauty collagen drinks with added biotin and vitamin C. The category has exploded.

And here’s what we see in the lab: the testing infrastructure hasn’t kept pace.

That’s not a criticism of every brand in the space. Some manufacturers do this right. But when we review Certificates of Analysis submitted during client onboarding — documents that are supposed to prove what’s in the product — we regularly encounter CoAs that confirm weight and microbial limits while leaving identity, type, and source entirely unverified. In a market growing this fast, with margins this healthy, that’s a compliance and liability problem waiting to crystallize.

The Label Says “Marine Collagen” — But How Would You Know?

Source authentication is one of the most misunderstood aspects of collagen testing. A label claiming “wild-caught marine collagen” is making two separate assertions: the source species (fish) and the sourcing method (wild-caught vs. farmed). Consumers pay a premium for both — sometimes 40–60% more than comparable bovine products.

The challenge is that hydrolyzed collagen peptides — which is what virtually every collagen supplement contains — have been enzymatically broken into short-chain amino acids. By the time collagen is hydrolyzed and dried into a white powder, the molecular characteristics that distinguish fish collagen from bovine or porcine are largely gone at the macroscopic level. You can’t verify source by looking at the powder, smelling it, or even running a basic amino acid panel.

Two methods give you reliable source authentication. The first is species-specific DNA testing, using PCR (polymerase chain reaction) to detect genetic markers that identify whether collagen is derived from fish, bovine, porcine, or chicken. This works even in processed matrices because small fragments of mitochondrial DNA survive hydrolysis in many cases. The second is stable isotope ratio analysis (SIRA), which differentiates marine-sourced proteins from land-animal sources based on isotopic signatures accumulated through the food chain.

Neither method is standard practice across the supplement industry. And without one of them, a brand relying solely on their supplier’s word is taking on blind faith that what’s in the bag matches what the label claims.

”Type I, II, III” Claims Outrun the Evidence

Collagen type claims are everywhere. “Type II for joints.” “Type I and III for skin and hair.” These claims carry real marketing weight — and they’re frequently impossible to verify without the right analytical approach.

Here’s the structural reality. Collagen types are differentiated primarily by their triple-helix chain composition. Type I collagen, the most abundant in the human body, is a heterotrimer of two α1(I) chains and one α2(I) chain. Type II is a homotrimer of three α1(II) chains. These distinctions exist at the intact protein level. Once you hydrolyze collagen into peptides — which, again, is what essentially all commercial collagen supplements are — those triple-helix structures are destroyed.

What that means practically: a “Type II collagen” supplement made from hydrolyzed chicken cartilage contains peptides derived from Type II collagen, but the intact type structure no longer exists in the product. An amino acid panel will show elevated hydroxyproline content consistent with collagen generally, but it won’t confirm Type II specifically without additional testing. ELISA (enzyme-linked immunosorbent assay) methods can detect Type-II-specific peptides in some formulations — particularly in undenatured Type II products where native structure is preserved — but those products require different handling and different test methods entirely.

The regulatory reality under 21 CFR Part 111 is that manufacturers must establish the identity, purity, strength, and composition of their dietary ingredients. An identity specification for a “Type II Collagen” supplement that only checks amino acid ratios and molecular weight distribution is not sufficient to substantiate the type claim. We’ve seen brands receive FDA warning letters for exactly this kind of specification gap — not because their product was harmful, but because their testing didn’t support what the label claimed.

Heavy Metals and the Marine Sourcing Problem

Marine-sourced collagen carries a contamination risk that deserves a direct conversation: heavy metals.

Fish accumulate heavy metals — particularly mercury (Hg), lead (Pb), arsenic (As), and cadmium (Cd) — through bioaccumulation in the food chain. Larger, longer-lived fish like tuna and swordfish carry higher mercury burdens. Most collagen manufacturers source from fish skin and scales, which tend to have lower heavy metal loads than muscle tissue, but the risk doesn’t disappear. Processing doesn’t eliminate inorganic heavy metals — those stay in the product regardless of how thoroughly you hydrolyze the protein.

FDA’s guidance on elemental impurities, which aligns with USP <232> and <233>, sets acceptable daily exposure limits for a range of elements. For lead, the oral PDE (permitted daily exposure) is 500 μg/day under USP. For cadmium, it’s also 500 μg/day. For inorganic arsenic — the toxic form — California’s Prop 65 framework sets a more restrictive threshold of 15 μg/day, which matters for any brand selling into that market.

At Qalitex, we run ICP-MS (inductively coupled plasma-mass spectrometry) panels on marine-sourced collagen products as part of our standard dietary supplement testing protocol. ICP-MS is the method of choice here because it detects these elements at parts-per-billion concentrations — sensitivity you simply cannot achieve with older flame AAS methods. Across marine collagen samples we tested in 2024, roughly 12% required a second-look calculation against serving size and projected daily dose before we could clear the product. That’s not a pass/fail figure — most of those products did clear — but it illustrates why skipping this test on marine-sourced materials is a genuine risk.

What 21 CFR Part 111 Actually Requires

Let’s be specific about the regulatory framework, because we find that many emerging supplement brands — particularly those launching collagen products for the first time — underestimate what the rule demands.

Under 21 CFR Part 111 (Current Good Manufacturing Practice for Dietary Supplements), manufacturers and packers are required to:

• Establish specifications for identity, purity, strength, and composition for each dietary ingredient and finished product (§111.70)
• Test or examine each lot of dietary ingredient before use (§111.75)
• Verify finished batch specifications are met before releasing product (§111.123)
• Retain records for at least one year beyond the product’s shelf life or two years from the date of manufacture, whichever is longer (§111.375)

The “test or examine” language in §111.75 is where many brands make a costly assumption: they interpret “examine” to mean reviewing a supplier’s CoA. FDA has clarified in multiple warning letters that relying on a supplier’s CoA without periodic independent verification does not satisfy the regulation’s intent. The rule requires a system to verify supplier testing — which, in practice, means periodically sending samples to an ISO 17025-accredited third-party lab to confirm that the supplier’s CoA reflects what’s actually in the material.

For collagen specifically, a compliant specification package should include: identity confirmation via DNA-based source authentication or FTIR spectroscopy; an amino acid profile demonstrating hydroxyproline levels consistent with collagen (collagen’s hydroxyproline content runs approximately 13–14% by weight — far higher than most other proteins, making it a reliable identity marker); a heavy metals panel by ICP-MS covering at minimum Pb, Cd, As, and Hg; microbial testing per USP <61> and <62>; and — if claiming a specific collagen type — a validated analytical method that actually supports that identity claim.

For EU market entry and European regulatory compliance, Care Europe provides expert consulting from Paris.

The Enforcement Window Is Closing

FDA’s supplement enforcement posture has been shifting. The agency has grown more aggressive about issuing warning letters and import alerts for products with identity issues, undeclared ingredients, and specification gaps. The collagen category, precisely because of its size and the premium pricing involved, is an obvious area of interest for both regulators and class-action plaintiffs. Consumer advocacy groups, including Consumer Reports, have published investigations finding label inaccuracies in popular collagen and protein products — the kind of reporting that tends to accelerate regulatory attention.

Brands that built their collagen lines on supplier trust and a single basic CoA have gotten away with it for years. That window is closing.

If you’re launching or reformulating a collagen supplement in 2026, build the testing infrastructure before you finalize the label. Validate the source claim with a method that can actually detect species. Confirm the type claim with an approach that distinguishes hydrolyzed peptides from undenatured protein as needed. Run the heavy metals panel — especially if you’re sourcing marine. And document everything as though someone is going to ask for it, because eventually, someone will.

The market will keep growing. Make sure your quality program grows with it.